Androgen Receptor Antagonists

DRUG2 trials

Sponsors

Medical University of South Carolina, Center of Molecular Immunology (CIM)

Conditions

Castration resistant prostate cancerProstate Cancer

Phase 2

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

TerminatedNCT00103376

Medical University of South CarolinaProstate Cancer

Start: 2004-10-31End: 2011-06-30Updated: 2018-11-05

Phase 3

CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial

Active, not recruitingRPCEC00000291

Center of Molecular Immunology (CIM)Castration resistant prostate cancer

Start: 2018-10-01Updated: 2026-03-30